What is a stock summary page? Click here for an overview.
Business Description
Relay Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US75943R1023
Share Class Description:
RLAY: Ordinary SharesDescription
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.11 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -0.06 | |||||
| Beneish M-Score | -3.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 29.8 | |||||
| 3-Year EBITDA Growth Rate | -4.3 | |||||
| 3-Year EPS without NRI Growth Rate | -1.1 | |||||
| 3-Year FCF Growth Rate | -29 | |||||
| 3-Year Book Growth Rate | -17.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 54.27 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.9 | |||||
| 9-Day RSI | 27.72 | |||||
| 14-Day RSI | 31.92 | |||||
| 3-1 Month Momentum % | -17.23 | |||||
| 6-1 Month Momentum % | -51.84 | |||||
| 12-1 Month Momentum % | -58.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.95 | |||||
| Quick Ratio | 15.95 | |||||
| Cash Ratio | 15.4 | |||||
| Days Sales Outstanding | 7.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.7 | |||||
| Shareholder Yield % | -56.64 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3854.04 | |||||
| Net Margin % | -3374.72 | |||||
| FCF Margin % | -2509.49 | |||||
| ROE % | -44.48 | |||||
| ROA % | -39.64 | |||||
| ROIC % | -503.83 | |||||
| 3-Year ROIIC % | -374.99 | |||||
| ROC (Joel Greenblatt) % | -608.86 | |||||
| ROCE % | -47.62 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.45 | |||||
| PB Ratio | 0.56 | |||||
| Price-to-Tangible-Book | 0.56 | |||||
| EV-to-EBIT | 0.7 | |||||
| EV-to-EBITDA | 0.71 | |||||
| EV-to-Revenue | -27.15 | |||||
| EV-to-Forward-Revenue | 3.47 | |||||
| EV-to-FCF | 1.08 | |||||
| Price-to-GF-Value | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 0.61 | |||||
| Price-to-Net-Cash | 0.64 | |||||
| Earnings Yield (Greenblatt) % | 142.86 | |||||
| FCF Yield % | -56.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RLAY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Relay Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.007 | ||
| EPS (TTM) ($) | -2.39 | ||
| Beta | 1.7 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.9 | ||
| Volatility % | 54.47 | ||
| 14-Day RSI | 31.92 | ||
| 14-Day ATR ($) | 0.274265 | ||
| 20-Day SMA ($) | 3.234 | ||
| 12-1 Month Momentum % | -58.92 | ||
| 52-Week Range ($) | 2.45 - 10.72 | ||
| Shares Outstanding (Mil) | 169.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Relay Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Relay Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Relay Therapeutics Inc Frequently Asked Questions
What is Relay Therapeutics Inc(RLAY)'s stock price today?
The current price of RLAY is $2.61. The 52 week high of RLAY is $10.72 and 52 week low is $2.45.
When is next earnings date of Relay Therapeutics Inc(RLAY)?
The next earnings date of Relay Therapeutics Inc(RLAY) is 2025-05-02 Est..
Does Relay Therapeutics Inc(RLAY) pay dividends? If so, how much?
Relay Therapeutics Inc(RLAY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers